RE:Re: Wow The Offering appears to be about 34% of the proforma numver of shares...Total pro forma market cap around 700 million,,,for a company with no revenues and still in early clinical stage and also they are obligated to pay an undisclosed royalty % to Stanford
Sigh of Envy!!!!!
Upon the closing of this offering, we will have 33,521,726 outstanding shares of common stock, after giving effect to the conversion of 20,843,334 outstanding shares of convertible preferred stock, which includes the conversion of the 5,611,059 shares of Series C-2 preferred stock we issued and sold in January 2021, into an equal number of shares of common stock, the issuance of shares of common stock upon the automatic net exercise of warrants and the shares sold through the directed share program described in “Underwriting”, assuming no exercise of the underwriters’ over-allotment option and no exercise of outstanding options.